News
Market and company headlines
BBOTAll
Loading
10:00Oct 201 Story
04:00Oct 191 Story
16:00Oct 121 Story
03:00Sep 121 Story
05:00Sep 111 Story
07:00Sep 101 Story
09:00-11:00Sep 93 Stories
Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.
Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.
06:00Sep 91 Story
08:00Aug 141 Story
16:00Aug 112 Stories
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026. The employees received non-qualified stock options to purchase an aggregate 65,350 shares of BBOT common s
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Continued to advance monotherapy and combination cohorts for all clinical programsInitiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models Cash runway expected to fund operations into 2028 SOUTH S